Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes

European Journal of Cardio-thoracic Surgery

Volumn 31, Issue 6, 2007, Pages 1058-1069

  Mangoush, Omar ^a   Purkayastha, Sanjay ^b   Haj Yahia, Saleem ^b   Kinross, James ^b,c   Hayward, Martin ^a   Bartolozzi, Fabio ^d   Darzi, Ara ^b,c   Athanasiou, Thanos ^b,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

Cardiopulmonary bypass; Heparin bonded circuit; Meta analysis; Perfusion

Indexed keywords

HEPARIN;

ASSISTED VENTILATION; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HEPARINIZATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS; MORTALITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; SYSTEMATIC REVIEW;

ANTICOAGULANTS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; HEPARIN; HUMANS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 34248387256     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.01.029     Document Type: Review

References (142)

1. Gott V.L., and Daggett R.L. Serendipity and the development of heparin and carbon surfaces. Ann Thorac Surg 68 (1999) S19-S22
2. Ishihara K., Oshida H., Endo Y., Ueda T., Watanabe A., and Nakabayashi N. Hemocompatibility of human whole blood on polymers with a phospholipid polar group and its mechanism. J Biomed Mater Res 26 (1992) 1543-1552
3. Alderson P, Green S, Higgins J. Cochrane Reviewers' Handbook 4.2.5 [updated December 2005] ed. Chichester: John Wiley & Sons, Ltd.; 2005.
4. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet (1999) 1896-1900
5. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., and McQuay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
6. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 719-748
7. Egger M., Davey S.G., Schneider M., and Miner C. Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 629-634
8. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
9. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
10. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
11. Martens S., Wimmer-Greinecker G., Matheis G., Feuerbach J., Jakob A., Scherer M., Westphal K., and Moritz A. Heparin-coated extracorporeal bypass circuits: Fibrinolysis and coagulation activity in a clinical trial. Zeitschrift fur Herz-, Thorax- und Gefasschirurgie 13 6 (1999) 267-272
12. Nilsson L., Peterson C., Venge P., Borowiec J.W., and Thelin S. Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Annal Thorac Surg 59 (1995) 713-716
13. Ashraf S., Tian Y., Cowan D., Entress A., Martin P.G., and Watterson K.G. Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: heparin-bonded versus nonbonded oxygenators. [comment]. Annal Thorac Surg 64 (1997) 1790-1794
14. Grossi E.A., Kallenbach K., Chau S., Derivaux C.C., Aguinaga M.G., Steinberg B.M., Kim D., Iyer S., Tayyarah M., Artman M., Galloway A.C., and Colvin S.B. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study. Annal Thorac Surg 70 (2000) 191-196
15. Ozawa T., Yoshihara K., Koyama N., Yamazaki S., and Takanashi Y. Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass. Jpn J Thorac Cardiovasc Surg 47 (1999) 592-599
16. Ozawa T., Yoshihara K., Koyama N., Watanabe Y., Shiono N., and Takanashi Y. Clinical efficacy of heparin-bonded bypass circuits related to cytokine responses in children. Annal Thorac Surg 69 (2000) 584-590
17. Schreurs H.H., Wijers M.J., Gu Y.J., van Oeveren W., van Domburg R.T., de Boer J.H., and Bogers A.J.J.C. Heparin-coated bypass circuits: Effects on inflammatory response in pediatric cardiac operations. Annal Thorac Surg 66 (1998) 166-171
18. Wan S., LeClerc J.L., Antoine M., DeSmet J.M., Yim A.P., and Vincent J.L. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study. Annal Thorac Surg 68 (1999) 1230-1235
19. Baufreton C., Moczar M., Intrator L., Jansen P.G., te V.H., Le Besnerais P., Farcet J.P., Wildevuur C.R., and Loisance D.Y. Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits. Perfusion 13 (1998) 419-427
20. Flom-Halvorsen H.I., Ovrum E., Brosstad F., Tangen G., Ringdal M.A.L., and Oystese R. Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction. Perfusion 17 (2002) 339-345
21. Jansen P.G., te V.H., Wildevuur W.R., Huybregts M.A., Bulder E.R., van der Spoel H.I., Sturk A., Eijsman L., and Wildevuur C.R. Cardiopulmonary bypass with modified fluid gelatin and heparin-coated circuits. Br J Anaesth 76 (1996) 13-19
22. Olsson C., Siegbahn A., Halden E., Nilsson B., Venge P., and Thelin S. No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits. Annal Thorac Surg 69 (2000) 743-749
23. Ovrum E., Tangen G., Oystese R., Ringdal M.A., and Istad R. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations. J Thorac Cardiovasc Surg 121 (2001) 324-330
24. Palanzo D.A., Zarro D.L., Manley N.J., Montesano R.M., Quinn M., Elmore B.A., Gustafson P.A., and Castagna J.M. Effect of Carmeda BioActive Surface coating versus Trillium Biopassive Surface coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass. Perfusion 16 (2001) 279-283
25. Belboul A., al Khaja N., Gudmundsson M., Karlsson H., Uchino T., Liu B., El Gatit A., Bjell A., Roberts D., and William-Olsson G. The influence of heparin-coated and uncoated extracorporeal circuits on blood rheology during cardiac surgery. J Extra-Corpor Technol 25 (1993) 40-46
26. Borowiec J., Bagge L., Saldeen T., and Thelin S. Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits. Thorac Cardiovasc Surg 45 (1997) 163-167
27. Bouma M., Maessen J., Weerwind P., Dentener M., Fransen E., de Jong D., and Buurman W. Release of lipopolysaccharide toxicity-modulating proteins in patients undergoing cardiopulmonary bypass using non-coated and heparin-coated extracorporeal circuits. A clinical pilot study. Chest 111 (1997) 577-583
28. Giomarelli P., Naldini A., Biagioli B., and Borrelli E. Heparin coating of extracorporeal circuits inhibits cytokine release from mononuclear cells during cardiac operations. Int J Artif Organs 23 (2000) 250-255
29. Gott J.P., Cooper W.A., Schmidt Jr. F.E., Brown III W.M., Wright C.E., Merlino J.D., Fortenberry J.D., Clark W.S., and Guyton R.A. Modifying risk for extracorporeal circulation: trial of four anti-inflammatory strategies. Annal Thorac Surg 66 (1998) 747-753
30. Hamada Y., Kawachi K., Nakata T., Kohtani T., Takano S., and Tsunooka N. Anti-inflammatory effect of heparin-coated circuits with leukocyte-depleting filters in coronary bypass surgery. Artif Organs 25 (2001) 1004-1008
31. Hatori N., Yoshizu H., Haga Y., Kusama Y., Takeshima S., Segawa D., and Tanaka S. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. Artif Organs 18 (1994) 904-910
32. Horton S.B., Butt W.W., Mullaly R.J., Thuys C.A., O'Connor E.B., Byron K., Cochrane A.D., Brizard C.P., and Karl T.R. IL-6 and IL-8 levels after cardiopulmonary bypass are not affected by surface coating. Annal Thorac Surg 68 (1999) 1751-1755
33. Jansen P.G.M., te V.H., Huybregts R.A.J.M., Paulus R., Bulder E.R., van der Spoel H.I., Bezemer P.D., Slaats E.H., Eijsman L., and Wildevuur C.R.H. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 110 (1995) 829-834
34. Jansen P.G.M., te V.H., Wildevuur W.R., Huybregts M.A.J.M., Bulder E.R., van der Spoel H.I., Sturk A., Eijsman L., and Wildevuur C.R.H. Cardiopulmonary bypass with modified fluid gelatin and heparin-coated circuits. Br J Anaesth 76 (1996) 13-22
35. Kagisaki K., Masai T., Kadoba K., Sawa Y., Nomura F., Fukushima N., Ichikawa H., Ohata T., Suzuki K., Taketani S., and Matsuda H. Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass. Artif Organs 21 (1997) 836-840
36. Kinjyo T., Ushijima T., Moriyama Y., Koga M., Saigenji H., Shimokawa S., and Taira A. Clinical evaluation of the heparine-coated bypass circuits. Jpn J Artif Organs 25 (1996) 90-93
37. Kumano H. Biocompatibility of heparin-coated circuits during cardiopulmonary bypass: Effects on inflammatory responses. Jpn J Artif Organs 27 (1998) 561-566
38. Lundblad R., Moen O., and Fosse E. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Annal Thorac Surg 63 (1997) 1361-1367
39. Misawa Y., Kawahito K., Konishi H., and Fuse K. Cytokine mediated endothelial activation during and after normothermic cardiopulmonary bypass: heparin-bonded versus nonheparin-bonded circuits. ASAIO J 46 (2000) 740-743
40. Misoph M., Babin-Ebell J., and Schwender S. A comparative evaluation of the effect of pump type and heparin-coated surfaces on platelets during cardiopulmonary bypass. Thorac Cardiovasc Surg 45 (1997) 302-306
41. Misoph M., Schwender S., and Babin-Ebell J. Response of the cellular immune system to cardiopulmonary bypass is independent of the applied pump type and of the use of heparin-coated surfaces. Thorac Cardiovasc Surg 46 (1998) 222-227
42. Moen O., Fosse E., Brockmeier V., Andersson C., Mollnes T.E., Hogasen K., and Venge P. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. Annal Thorac Surg 60 (1995) 1317-1323
43. Moen O., Fosse E., Dregelid E., Brockmeier V., Andersson C., Hogasen K., Venge P., Mollnes T.E., and Kierulf P. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility. Annal Thorac Surg 62 (1996) 1134-1140
44. Moen O., Hogasen K., Fosse E., Dregelid E., Brockmeier V., Venge P., Harboe M., and Mollnes T.E. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Annal Thorac Surg 63 (1997) 105-111
45. Mongero L.B., Beck J.R., Manspeizer H.E., Heyer E.J., Lee K., Spanier T.A., and Smith C.R. Cardiac surgical patients exposed to heparin-bonded circuits develop less postoperative cerebral dysfunction than patients exposed to nonheparin-bonded circuits. Perfusion 16 (2001) 107-111
46. Nakajima T., Osawa S., Ogawa M., Sasaki T., Izumoto H., Yagi Y., and Kawazoe K. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment. ASAIO J 42 (1996) 301-305
47. Ovrum E., Brosstad F., Am H.E., Tangen G., Abdelnoor M., and Oystese R. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis. Eur J Cardiothorac Surg 10 (1996) 449-455
48. Pekna M., Borowiec J., Fagerhol M.K., Venge P., and Thelin S. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 28 (1994) 5-11
49. Pekna M., Hagman L., Halden E., Nilsson U.R., Nilsson B., and Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Annal Thorac Surg 58 (1994) 421-424
50. Spiess B.D., Vocelka C., Cochran R.P., Soltow L., and Chandler W.L. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 12 (1998) 299-304
51. te V.H., Baufreton C., Jansen P.G., Thijs C.M., Hack C.E., Sturk A., Wildevuur C.R., and Loisance D.Y. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg 114 (1997) 117-122
52. van der Kamp K.W., and van Oeveren W. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery. Int J Artif Organs 16 (1993) 836-842
53. Weerwind P.W., Maessen J.G., van Tits L.J., Stad R.K., Fransen E.J., de Jong D.S., and Penn O.C. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 110 (1995) 1633-1641
54. Yamada H., Kudoh I., Hirose Y., Toyoshima M., Abe H., and Kurahashi K. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass. Acta Anaesthesiol Scand 40 (1996) 311-317
55. Yamanaka J., Takeuti Y., Gomi A., and Torii S. The evaluation of the heparin-coated cardiopulmonary bypass circuits, coagulation, fibrinolysis, complement activation. Jpn J Artif Organs 24 (1995) 541-543
56. Baufreton C., and de Brux J.L. Coagulation, fibrinolysis, and cell activation in patients and in shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 126 (2003) 2116
57. Kazaz H., Oto O., Sariosmanoglu N., and Hazan E. The effects of heparin coated circuits on pulmonary injury. A clinical study. J Cardiovasc Surg (Torino) 44 (2003) 611-615
58. Klingel R., Schaefer M., Schwarting A., Himmelsbach F., Altes U., Uhlenbusch-Korwer I., and Hafner G. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation. Nephrol Dial Transplant 19 (2004) 164-170
59. Lindholm L., Westerberg M., Bengtsson A., Ekroth R., Jensen E., and Jeppsson A. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients. Ann Thorac Surg 78 (2004) 2131-2138
60. Svenmarker S., Haggmark S., Jansson E., Lindholm R., Appelblad M., Sandstrom E., and Aberg T. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome. Scand Cardiovasc J 36 (2002) 241-246
61. Johnell M., Larsson R., Thelin S., and Siegbahn A. Coagulation and fibrinolysis during coronary artery bypass grafting using a new heparin-coated surface. Thromb Haemost (1999) 773
62. Khuri S.F., Healey N.A., Hassanein W.H., Birjiniuk V., Crittenden M.D., Tyrrell T.A., Treanor P.A., Bauer K., and Valeri R. Advantages of low dose heparin and heparin bonded surfaces during cardiopulmonary bypass (CPB). Circulation 98 Suppl (1998) 526-1526
63. Martens S., Matheis G., Wimmer-Greinecker G., Feuerbach J., Jakob A., Mierdl S., and Moritz A. Heparin coating of the extracorporeal circuit combined with leukocyte filtration reduces coagulation activity, blood loss and blood product substitution. Int J Artif Organs 24 (2001) 484-488
64. Belboul A., Akbar O., Lofgren C., Jungbeck M., Storm C., and Roberts A. Improved blood cellular biocompatibility with heparin coated circuits during cardiopulmonary bypass. J Cardiovasc Surg 41 (2000) 357-362
65. Harig F., Feyrer R., Mahmoud F.O., Blum U., and von der E.J. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac Cardiovasc Surg 47 (1999) 111-118
66. Videm V., Mollnes T.E., Bergh K., Fosse E., Mohr B., Hagve T.A., Aasen A.O., and Svennevig J.L. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. J Thorac Cardiovasc Surg 117 (1999) 803-809
67. te V.H., Jansen P.G., Hack C.E., Eijsman L., and Wildevuur C.R. Specific complement inhibition with heparin-coated extracorporeal circuits. Annal Thorac Surg 61 (1996) 1153-1157
68. Ranucci M., Cirri S., Conti D., Ditta A., Boncilli A., Frigiola A., and Menicanti L. Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction. Annal Thorac Surg 61 (1996) 76-81
69. Ernofsson M., Thelin S., and Siegbahn A. Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits. Scand J Thorac Cardiovascular Surg 29 (1995) 157-165
70. Ovrum E., Brosstad F., Am H.E., Tangen G., and Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 92 (1995) 2579-2584
71. Ovrum E., Holen E.A., Tangen G., Brosstad F., Abdelnoor M., Ringdal M.A., Oystese R., and Istad R. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Annal Thorac Surg 60 (1995) 365-371
72. Borowiec J., Thelin S., Bagge L., Nilsson L., Venge P., and Hansson H.E. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. Journal of Thoracic & Cardiovascular Surgery 104 (1992) 642-647
73. Mirow N., Minami K., Reiss N., Knobl H., Kind K., and Korfer R. Heparin coated extracorporeal circulation and low dose heparinization: Technical considerations and specific risks. Cardiovasc Eng 5 (2000) 11-15
74. Aldea G.S. Heparin-bonded circuits decrease thromboembolic complications and improve outcomes in patients undergoing coronary artery bypass graft surgery. Semin Cardiothorac Vasc Anesth 3 (1999) 9-16
75. Ovrum E., Mollnes T.E., Fosse E., Am H.E., Tangen G., Ringdal M.-A., and Videm V. High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Annal Thorac Surg 60 (1995) 1755-1761
76. Svenmarker S., Sandstrom E., Karlsson T., Haggmark S., Jansson E., Appelblad M., Lindholm R., and Aberg T. Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits. Eur J Cardiothorac Surg 19 (2001) 47-53
77. Wimmer-Greinecker G., Matheis G., Martens S., Oremek G., Abdel-Rahman U., and Moritz A. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences. Eur J Cardiothorac Surg 16 (1999) 211-217
78. McCarthy P.M., Yared J.P., Foster R.C., Ogella D.A., Borsh J.A., and Cosgrove III D.M. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations. Annal Thorac Surg 67 (1999) 1268-1273
79. Belboul A., and al Khaja N. Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery. Perfusion 12 (1997) 385-391
80. Svenmarker S., Sandstrom E., Karlsson T., Jansson E., Haggmark S., Lindholm R., Appelblad M., and Aberg T. Clinical effects of the heparin coated surface in cardiopulmonary bypass. Eur J Cardiothorac Surg 11 (1997) 957-964
81. Wildevuur C.R., Jansen P.G., Bezemer P.D., Kuik D.J., Eijsman L., Bruins P., De Jong A.P., Van Hardevelt F.W., Biervliet J.D., Hasenkam J.M., Kure H.H., Knudsen L., Bellaiche L., Ahlburg P., Loisance D.Y., Baufreton C., Le Besnerais P., Bajan G., Matta A., Van Dyck M., Renotte M.T., Ponlot-Lois A., Baele P., McGovern E.A., and Ahlvin E. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. Eur J Cardiothorac Surg 11 (1997) 616-623
82. Ernofsson M., Thelin S., and Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 113 (1997) 576-584
83. Ovrum E., Am H.E., Tangen G., and Ringdal M.A. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance. Annal Thorac Surg 62 (1996) 1128-1133
84. Barstad R.M., Ovrum E., Ringdal M.A., Oystese R., Hamers M.J., Veiby O.P., Rolfsen T., Stephens R.W., and Sakariassen K.S. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol 94 (1996) 517-525
85. Ovrum E., Fosse E., Mollnes T.E., Am H.E., Tangen G., Abdelnoor M., Ringdal M.A., Oystese R., and Venge P. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur J Cardiothorac Surg 10 (1996) 54-60
86. Unsworth-White M.J., Kallis P., Cowan D., Tooze J.A., Bevan D.H., and Treasure T. A prospective randomised controlled trial of postoperative autotransfusion with and without a heparin-bonded circuit. Eur J Cardiothorac Surg 10 (1996) 38-47
87. Muehrcke D.D., McCarthy P.M., Kottke-Marchant K., Harasaki H., Pierre-Yared J., Borsh J.A., Ogella D.A., and Cosgrove D.M. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial. J Thorac Cardiovasc Surg 112 (1996) 472-483
88. Ovrum E., Mollnes T.E., Fosse E., Holen E.A., Tangen G., Abdelnoor M., Ringdal M.A., Oystese R., and Venge P. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg 110 (1995) 1623-1632
89. Sellevold O.F., Berg T.M., Rein K.A., Levang O.W., Iversen O.J., and Bergh K. Heparin-coated circuit during cardiopulmonary bypass. A clinical study using closed circuit, centrifugal pump and reduced heparinization. Acta Anaesthesiol Scand 38 (1994) 372-379
90. Gorman R.C., Ziats N.P., Rao A.K., Gikakis N., Sun L., Khan M.M.H., Stenach N., Sapatnekar S., Chouhan V., Gorman III J.H., Niewiarowski S., Colman R.W., Anderson J.M., Edmunds Jr. L.H., Khuri S.F., Magovern G.J., Hill R.C., and von Segesser L.K. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 111 (1996) 1-12
91. Mullen J.C., Bentley M.J., Gelfand E.T., Koshal A., Modry D.L., Guenther C.R., Etches W.S., Stang L.J., and Lopushinsky S.R. Coronary artery bypass surgery with heparin-coated perfusion circuits and low-dose heparinization. Can J Surg 45 (2002) 166-172
92. Palanzo D.A., Zarro D.L., Montesano R.M., Manley N.J., Quinn M., Elmore B.A., Gustafson P.A., and Castagna J.M. Effect of Trillium Biopassive Surface coating of the oxygenator on platelet count drop during cardiopulmonary bypass. Perfusion 14 (1999) 473-479
93. Hoel T.N., Videm V., Baksaas S.T., Mollnes T.E., Brosstad F., and Svennevig J.L. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery. Perfusion 19 (2004) 177-184
94. Weerwind P.W., Caberg N.E., Reutelingsperger C.P., Lindhout T., and de Jong D.S. Exposure of procoagulant phospholipids on the surface of platelets in patients undergoing cardiopulmonary bypass using non-coated and heparin-coated extracorporeal circuits. Int J Artif Organs 25 (2002) 770-776
95. Ranucci M., Cazzaniga A., Soro G., Isgro G., Frigiola A., and Menicanti L. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. J Cardiothorac Vasc Anesth 16 (2002) 316-320
96. Johnell M., Elgue G., Larsson R., Larsson A., Thelin S., and Siegbahn A. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 124 (2002) 321-332
97. Butler J., Murithi E.W., Pathi V.L., MacArthur K.J., and Berg G.A. Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function. Annal Thorac Surg 74 (2002) 139-142
98. Harig F., Hohenstein B., von der E.J., and Weyand M. Modulating IL-6 and IL-10 levels by pharmacologic strategies and the impact of different extracorporeal circulation parameters during cardiac surgery. Shock 16 Suppl 1 (2001) 33-38
99. Collart F., Caus T., Pomane C., Pellissier V., Chi Y., Monties J.R., and Mesana T. Clinical evaluation of heparin-coated circuits for routine coronary artery bypass grafting surgery: a prospective randomized study. Artif Organs 24 (2000) 611-613
100. Belboul A., Lofgren C., Storm C., and Jungbeck M. Heparin-coated circuits reduce occult myocardial damage during CPB: a randomized, single blind clinical trial. Eur J Cardiothorac Surg 17 (2000) 580-586
101. Shimamoto A., Kanemitsu S., Fujinaga K., Takao M., Onoda K., Shimono T., Tanaka K., Shimpo H., and Yada I. Biocompatibility of silicone-coated oxygenator in cardiopulmonary bypass. Annal Thorac Surg 69 (2000) 115-120
102. Mahoney C.B., and Lemole G.M. Transfusion after coronary artery bypass surgery: the impact of heparin-bonded circuits. Eur J Cardiothorac Surg 16 (1999) 206-210
103. Sinci V., Kalaycioglu S., Gunaydin S., Imren Y., Gokgoz L., Soncul H., and Ersoz A. Evaluation of heparin-coated circuits with full heparin dose strategy. Annal Thorac Cardiovasc Surg 5 (1999) 156-163
104. Ranucci M., Mazzucco A., Pessotto R., Grillone G., Casati V., Porreca L., Maugeri R., Meli M., Magagna P., Cirri S., Giomarelli P., Lorusso R., and de Jong A. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Annal Thorac Surg 67 (1999) 994-1000
105. Videm V., Mollnes T.E., Fosse E., Mohr B., Bergh K., Hagve T.A., Aasen A.O., and Svennevig J.L. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg 117 (1999) 794-802
106. Parolari A., Alamanni F., Gherli T., Salis S., Spirito R., Foieni F., Rossi F., Bertera A., Oddono P., and Biglioli P. 'High dose' aprotinin and heparin-coated circuits: clinical efficacy and inflammatory response. Cardiovasc Surg 7 (1999) 117-127
107. Inui K., Shimazaki Y., Watanabe T., Takahashi T., Minowa T., Takeda H., Yanagawa N., and Sotoda Y. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids. Artif Organs 23 (1999) 1107-1112
108. Tamim M., Demircin M., Guvener M., Peker O., and Yilmaz M. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass. Panminerva Med 41 (1999) 193-198
109. Fosse E., Thelin S., Svennevig J.L., Jansen P., Mollnes T.E., Hack E., Venge P., Moen O., Brockmeier V., Dregelid E., Halden E., Hagman L., Videm V., Pedersen T., and Mohr B. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg 11 (1997) 320-327
110. Baufreton C., Jansen P.G., Le Besnerais P., te V.H., Thijs C.M., Wildevuur C.R., and Loisance D.Y. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Annal Thorac Surg 63 (1997) 50-56
111. Baufreton C., Le Besnerais P., Jansen P., Mazzucotelli J.P., Wildevuur C.R., and Loisance D.Y. Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass. Perfusion 11 (1996) 437-443
112. Hamulu A., Discigil B., Ozbaran M., Calkavur T., Kara E., Kokuludag A., Buket S., and Bilkay O. Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients. Perfusion 11 (1996) 333-337
113. Bozdayi M., Borowiec J., Nilsson L., Venge P., Thelin S., and Hansson H.E. Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery. Artif Organs 20 (1996) 1008-1016
114. Fukutomi M., Kobayashi S., Niwaya K., Hamada Y., and Kitamura S. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment. Artif Organs 20 (1996) 767-776
115. Saenz A., Larranaga G., Alvarez L., Greco E., Marrero A., Lunar M., Elosegui C., Ubago J.L., and Gallo I. Heparin-coated circuit in coronary surgery. A clinical study. Eur J Cardiothorac Surg 10 (1996) 48-53
116. Aldea G.S., Doursounian M., O'Gara P., Treanor P., Shapira O.M., Lazar H.L., and Shemin R.J. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Annal Thorac Surg 62 (1996) 410-417
117. Jansen P.G., Baufreton C., Le Besnerais P., Loisance D.Y., and Wildevuur C.R. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Annal Thorac Surg 61 (1996) 1363-1366
118. Jansen P.G., te V.H., Huybregts R.A., Paulus R., Bulder E.R., van der Spoel H.I., Bezemer P.D., Slaats E.H., Eijsman L., and Wildevuur C.R. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 110 (1995) 829-834
119. Boonstra P.W., Gu Y.J., Akkerman C., Haan J., Huyzen R., and van Oeveren W. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. J Thorac Cardiovasc Surg 107 (1994) 289-292
120. Pradhan M.J., Fleming J.S., Nkere U.U., Arnold J., Wildlevuur C.R., and Taylor K.M. Clinical experience with heparin-coated cardiopulmonary bypass circuits. Perfusion 6 (1991) 235-242
121. Aldea G.S., Soltow L.O., Chandler W.L., Triggs C.M., Vocelka C.R., Crockett G.I., Shin Y.T., Curtis W.E., and Verrier E.D. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 123 (2002) 742-755
122. Mirow N., Brinkmann T., Minami K., Tenderich G., Schulte-Eistrup S., Kleesiek K., and Korfer R. Low dose systemic heparinization combined with heparin-coated extracorporeal circulation. Effects related to platelets. J Cardiovasc Surg 42 (2001) 579-585
123. Defraigne J.-O., Pincemail J., Larbuisson R., Blaffart F., and Limet R. Cytokine release and neutrophil activation are not prevented by heparin- coated circuits and aprotinin administration. Annal Thorac Surg 69 (2000) 1084-1091
124. Shiiya N., Ikeda H., Matsuzaki K., Watanabe M., Matsui Y., Sekiguchi S., and Yasuda K. Does a heparin-coated cardiopulmonary bypass circuit favorably affect hemostatic function?. Jpn J Artif Organs 27 (1998) 418-422
125. Kuitunen A.H., Heikkila L.J., and Salmenpera M.T. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation. Annal Thorac Surg 63 (1997) 438-444
126. Borowiec J.W., Hagman L., Totterman T.H., Pekna M., Venge P., and Thelin S. Circulating cytokines and granulocyte-derived enzymes during complex heart surgery. Scand J Thorac Cardiovasc Surg 29 (1995) 167-174
127. Gu Y.J., van Oeveren W., Akkerman C., Boonstra P.W., Huyzen R.J., and Wildevuur C.R.H. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Annal Thorac Surg 55 (1993) 917-922
128. Heyer E.J., Lee K.S., Manspeizer H.E., Mongero L., Spanier T.B., Caliste X., Esrig B., and Smith C. Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J Cardiothorac Vasc Anesth 16 (2002) 37-42
129. Borowiec J., Thelin S., Bagge L., Hultman J., and Hansson H.E. Decreased blood-loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 26 (1992) 177-185
130. Wagner W.R., Johnson P.C., Thompson K.A., and Marrone G.C. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg 58 (1994) 734-740
131. Tayama E., Hayashida N., Akasu K., Kosuga T., Fukunaga S., Akashi H., Kawara T., and Aoyagi S. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif Organs 24 (2000) 618-623
132. Palatianos G.M., Foroulis C.N., Vassili M.I., Astras G., Triantafillou K., Papadakis E., Lidoriki A.A., Iliopoulou E., and Melissari E.N. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit. Ann Thorac Surg 76 (2003) 129
133. Oliver Jr. W.C., Nuttall G.A., Ereth M.H., Santrach P.J., Buda D.A., and Schaff H.V. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 17 (2003) 165-170
134. de Vroege R., van Oeveren W., van Klarenbosch J., Stooker W., Huybregts M.A., Hack C.E., van Barneveld L., Eijsman L., and Wildevuur C.R. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg 98 (2004) 1586-1594 table
135. Cosgrove D.M., Loop F.D., Lytle B.W., Gill C.C., Golding L.R., Taylor P.C., and Forsythe S.B. Determinants of blood utilization during myocardial revascularization. Ann Thorac Surg (1985) 380-384
136. Karkouti K., Cohen M.M., McCluskey S.A., and Sher G.D. A multivariable model for predicting the need for blood transfusion in patients undergoing first-time elective coronary bypass graft surgery. Transfusion (2001) 1193-1203
137. Birrer M., Mahler F., Baumgartner I., Triller J., and Do D.D. Parallel stent placement for maldeployed iliac stent. Eur J Vasc Endovasc Surg 21 (2001) 572-574
138. Stammers A.H., Christensen K.A., Lynch J., Zavadil D.P., Deptula J.J., and Sydzyik R.T. Quantitative evaluation of heparin-coated versus nonheparin-coated bypass circuits during cardiopulmonary bypass. J Extra-Corpor Technol 31 (1999) 135-141
139. Mahoney C.B. Heparin-bonded circuits: clinical outcomes and costs. Perfusion 13 (1998) 192-204
140. Choi P.T., Halpern S.H., Malik N., Jadad A.R., Tramer M.R., and Walder B. Examining the evidence in anesthesia literature: a critical appraisal of systematic reviews. Anesth Analg 92 (2001) 700-709
141. Moher D., Jones A., and Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 285 (2001) 1992-1995
142. Soares H.P., Daniels S., Kumar A., Clarke M., Scott C., Swann S., and Djulbegovic B. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 328 (2004) 22-24